Compare Snowflake Inc (SNOW) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Snowflake Inc vs Sanofi SA — how do they compare? Snowflake Inc trades at $333.68 (market cap $116.01B), while Sanofi SA trades at $43.61 (market cap $104.30B). The key difference: Snowflake Inc and Sanofi SA are close in size by market cap, and Sanofi SA pays a 5.55% dividend while Snowflake Inc pays none. Which is the better fit depends on your goals.
| SNOW | SNY | |
|---|---|---|
Market Cap | $116.01B | $104.30B |
Sector | Technology | Health |
52-Week High | $334.70 | $52.34 |
52-Week Low | $121.11 | $41.33 |
Enterprise Value | $115.82B | $124.19B |
Dividend Yield | — | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Snowflake trades at $339.00, up 1.28% with bullish technical signals and strong analyst support (81% buy ratings). The company shows impressive revenue growth from $1.2B in 2022 to $3.6B in 2025, though remains unprofitable with a -23.79% net margin. Recent earnings beats and AI platform expansions drive optimism, but premium valuation at 22.66x P/S ratio presents risk.
Outlook remains positive with AI data cloud leadership and 30% revenue growth guidance, but investors face valuation concerns and persistent losses. Key catalysts include Q2 2026 earnings on September 2nd and enterprise AI adoption trends. The stock trades near resistance at $341 with consensus price target of $302.18 suggesting limited near-term upside.
SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.
Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
